LALPATHLAB vs SURAKSHA: Stock Comparison
DR. LAL PATH LABS is the larger company by market capitalisation. DR. LAL PATH LABS shows a higher ROE, a higher dividend yield and lower leverage, while SURAKSHA DIAGNOSTIC shows a lower P/E and faster revenue growth. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
LALPATHLAB leads 7; SURAKSHA leads 6 of 13
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | LALPATHLAB | SURAKSHA |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Healthcare Service Provider | Healthcare Service Provider |
Price
| Metric | LALPATHLAB | SURAKSHA |
|---|---|---|
| Live Price | ₹1,952.3 | ₹343.3 |
| Day Change | -0.46% | -3.57% |
| Volume | 4.52 L | 37,699 |
| 52-Week High | ₹3,313.3 | ₹360 |
| 52-Week Low | ₹1,272.6 | ₹224.1 |
| Distance from 52W High | -41.08% | -4.64% |
Valuation
| Metric | LALPATHLAB | SURAKSHA |
|---|---|---|
| Market Cap | ₹32,658 Cr | ₹1,794 Cr |
| P/E Ratio | 60.35x | 50.13x |
| P/B Ratio | 13.04x | 7.33x |
| EPS | ₹9.9 | ₹2.5 |
| Book Value | ₹151.59 | ₹46.75 |
| Dividend Yield | 1% | 0.28% |
Growth
| Metric | LALPATHLAB | SURAKSHA |
|---|---|---|
| Revenue Growth (TTM YoY) | 16.6% | 31.2% |
| EPS Growth (TTM YoY) | -15.4% | -5.4% |
| Qtr Sales Growth | -4.17% | 4.23% |
| Qtr Profit Growth | -2.7% | 2.09% |
Profitability & Leverage
| Metric | LALPATHLAB | SURAKSHA |
|---|---|---|
| ROE | 20.06% | 13.64% |
| ROCE | 22.94% | 17.24% |
| Net Margin | 18.27% | 10.37% |
| Operating Margin | 25.04% | 19.81% |
| Debt to Equity | 0x | 0.01x |
Shareholding
As of Jun 2026 • change vs previous quarter| Metric | LALPATHLAB | SURAKSHA |
|---|---|---|
| Promoter Holding | 51.35%▼ 0.02 pp | 49.1% |
| FII Holding | 17.36%▲ 0.18 pp | 13.47%▲ 0.01 pp |
| DII Holding | 21.59%▲ 0.21 pp | 23.23%▲ 0.09 pp |
| Public Holding | 7.47%▼ 0.4 pp | 14.21%▼ 0.1 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: DR. LAL PATH LABS and SURAKSHA DIAGNOSTIC.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.